Latest Breaking News On - மனம் உயிர் அறிவியல் - Page 5 : comparemela.com

NeonMind Biosciences Inc: NeonMind Purchases GMP Grade Synthetic Psilocybin from Psygen Labs for Phase 2 Human Clinical Trial

NeonMind Biosciences Inc: NeonMind Purchases GMP Grade Synthetic Psilocybin from Psygen Labs for Phase 2 Human Clinical Trial
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomBritish columbiaDanny motykaTrevor millarMelanie barbeauRob tessaroloJeffb smithExvera communications incUniversity of albertaRenmark financial communications incUniversity of british columbiaA harvard school of public healthCanadian securities exchangeCompany groupEdge communicationsWorld health organization

Preclinical trial underway exploring use of magic mushrooms to treat obesity - BC News

Preclinical trial underway exploring use of magic mushrooms to treat obesity - BC News
castanet.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from castanet.net Daily Mail and Mail on Sunday newspapers.

United kingdomBritish columbiaPeter dejongC laird birminghamUniversity of british columbiaNeonmind biosciences incVancouver based neonmind biosciencesMind biosciencesஒன்றுபட்டது கிஂக்டம்பிரிட்டிஷ் கொலம்பியாபீட்டர் டெஜோங்பல்கலைக்கழகம் ஆஃப் பிரிட்டிஷ் கொலம்பியாமனம் உயிர் அறிவியல்

FIELD TRIP HEALTH LTD by Field Trip Health Ltd (FTRPF), HAVN Life Sciences (HAVLF), MIND MEDICINE MINDMED by MIND MEDICINE MINDMED INC (MMEDF) - Psyched: First Psychedelics ETF Debuts; Hawaii, Florida and Connecticut Eye Psilocybin Legalization; Psyence Goes Public

The Horizons Psychedelic Stock Index ETF is now listed on Toronto’s NEO exchange under the symbol ‘PSYK’, and managed by Horizons ETFs Management. PSYK is a passive ETF, meaning that it’s not actively managed. The ETF follows the North American Psychedelics Index, an index owned and operated by Horizons and Solactive AG, which aims to replicate the performance of North American publicly-listed life sciences companies that are involved in the psychedelics industry. Horizons’ criteria for choosing members of the index requires companies to be listed on a stock exchange in Canada or in the U.S. and be engaged in research, production or distribution of psychedelic compounds and medicines. Companies must have a minimum market cap of CA$25 million ($19.6 million) to qualify, and remain above the CA$20 million mark.

United statesUnited kingdomLaura clint acasioLes ihara jrMichael griecoRobert tessaroloDaniel carcilloStanley changMaile shimabukuroConscious fundPsyence group incMedicinal psilocybin working groupWesana healthDepartment of healthCambria capitalField trip health

NeonMind Biosciences Inc: NeonMind Appoints Dr Frank Russo to Lead Development of Music-Based Program for Psilocybin Clinical Trials

NeonMind Biosciences Inc: NeonMind Appoints Dr. Frank Russo to Lead Development of Music-Based Program for Psilocybin Clinical Trials NeonMind Biosciences Inc. ( CSE: NEON) ( NeonMind ) a company conducting research into the potentially therapeutic uses of compounds found in psychedelic mushrooms, is pleased to announce that it has added Frank Russo as an advisor and consultant to assist the Company in selecting or developing music playlists for its clinical trials or for use with treatments to support optimum mental health. NeonMind Engages Music Expert Dr. Frank Russo To view an enhanced version of this graphic, please visit: https://orders.newsfilecorp.com/files/7646/72039 img1a.jpg

United kingdomBritish columbiaFrank russoCanadian psychological associationExvera communications incMassey collegeUniversity of toronto musicPsychology at ryerson universityMcmaster institute for musicScience of music auditory researchCanadian acoustical associationUniversity of british columbiaCanadian securities exchangeToronto rehabilitation instituteLab at ryersonEdge communications

NeonMind Biosciences Inc: NeonMind Engages Dr C Laird Birmingham to Develop Protocols for Phase 2 Clinical Trial Using Psilocybin to Treat Obesity

NeonMind Biosciences Inc: NeonMind Engages Dr. C. Laird Birmingham to Develop Protocols for Phase 2 Clinical Trial Using Psilocybin to Treat Obesity NeonMind Biosciences Inc. (CSE: NEON) ( NeonMind ), a psychedelic drug development company, is pleased to announce that it has engaged Dr. C. Laird Birmingham to consult with NeonMind to develop protocols for its Phase 2 Clinical Trial administering psilocybin to treat obese patients. Dr. Birmingham is a Specialist in Internal Medicine, an Epidemiologist and Biostatistician, and a Professor of Psychiatry at the University of British Columbia where he was previously Professor of Internal Medicine, and he has extensive experience in the design of clinical trials for treatments for eating disorders. He has also been appointed to NeonMind s Board of Advisors.

United kingdomBritish columbiaC laird birminghamMember of the brain research centreExvera communications incCentre for health evaluationWorld health organizationEdge communicationsWoodstone residential treatment centre for eating disordersBritish columbia newsfile corpUniversity of british columbiaNeonmind biosciences incCanadian securities exchangeOutcome sciencesMind biosciencesInternal medicine